Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2- Early Breast Cancer.

Drugs · 2025 · PMC11802638 · PMID 39820840

Europe PMC DOI

hedged sentence

0.0664

closest p · 1.3× alpha

0.0664

boldest claim

The sentences

did not reach statistical significanceP = 0.0664so close (0.05 < p ≤ 0.1)

Median OS was numerically improved from 53.7 to 66.8 months in the abemaciclib group; this difference, however, did not reach statistical significance (HR 0.804; 95% CI 0.637–1.015; P = 0.0664) [ 69 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.